What are the National Comprehensive Cancer Network (NCCN) guidelines for second-line therapy to treat predominantly clear cell renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

For patients with previously treated predominantly clear cell renal cell cancer, NCCN considerations for subsequent therapy include the following:

  • Clinical trial
  • Cabozantinib (category 1, preferred)
  • Nivolumab (category 1, preferred)
  • Axitinib (category 1)
  • Lenvatinib + everolimus (category 1)
  • Everolimus
  • Pazopanib
  • Sorafenib • Sunitinib
  • Bevacizumab (category 2B)
  • High-dose IL-2 for selected patientsj (category 2B)
  • Temsirolimus (category 2B)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!